Integrated Shield riders: Fresh focus on cancer drug cover, brace for premium hikes
IP riders now have additional cancer drug benefits far more than the base plans, raising the question of whether current premiums are sustainable
RIDERS to supplement private Integrated Shield Plans (IPs) are set to take on new significance for policyholders, particularly if you are concerned about the extent of cancer drug coverage.
The big question is – are today’s rider premiums sustainable given the riders’ enlarged role in outpatient cancer cover?
Insurers in the IP scheme recently rolled out their base IP plans and riders, with reference to the caps for cancer drug coverage, in line with the cancer drug list (CDL) issued by the health ministry last year.
TRENDING NOW
Qatari LNG ship struck in Strait of Hormuz, testing US talks
DBS, OCBC and UOB shares hit all-time highs as sentiment improves
‘Baptism of fire’: Andre Khor on leading Singapore refiner Aster through an energy crisis
Singapore retains top spot as most expensive city for HNWIs, with five Apac cities in global top 10